Sumatriptan (Imigran)

A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.

Also Known As:

Imigran; 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide; GR-43175; Sumatriptan Succinate; GR 43175; GR43175; Succinate, Sumatriptan; 1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-

Networked: 1601 relevant articles (382 outcomes, 423 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Olesen, Jes: 18 articles (12/2022 - 04/2011)
2.	Dehpour, Ahmad Reza: 17 articles (03/2024 - 01/2018)
3.	Derry, Sheena: 16 articles (04/2016 - 04/2006)
4.	Moore, R Andrew: 15 articles (04/2016 - 01/2010)
5.	Ashina, Messoud: 14 articles (12/2022 - 04/2011)
6.	Tfelt-Hansen, Peer: 14 articles (12/2021 - 12/2006)
7.	Rapoport, Alan M: 14 articles (01/2019 - 01/2004)
8.	Tepper, Stewart J: 13 articles (01/2022 - 02/2003)
9.	Cady, Roger K: 12 articles (12/2017 - 11/2002)
10.	Cady, Roger: 12 articles (01/2015 - 01/2002)

Related Diseases

1.	Migraine Disorders (Migraine) 01/01/2003 - "The goal of this study was to determine whether migraine management is improved by providing 3 formulations of sumatriptan succinate to patients, together with education to assist them in selecting the most appropriate formulation for specific attacks. " 05/28/2014 - "Information about the relative efficacy of the different routes of administration for different outcomes should help to inform decisions about the suitability of sumatriptan as a migraine treatment, as well as about the most appropriate way to administer the treatment for individual patients." 05/01/2007 - "The 5-HT(1B/1D) receptor agonist sumatriptan is highly effective in the treatment of migraine. " 04/22/1999 - "Sumatriptan is a highly effective treatment for migraine in adults but its efficacy in children has not been determined. " 02/01/1997 - "Sumatriptan has been shown to be most effective in migraine attacks, but with transient, slight side effects and high rebound attack rates. "
2.	Headache (Headaches) 04/01/1993 - "In addition, they examine the initial efficacy of treatment and the mechanism of recurrence of headache within 24 hours, which is the most important drawback of sumatriptan in clinical practice, next to its possible cardiac side effects." 01/01/2005 - "A single dose of sumatriptan 10 mg (approved European dosage) was significantly more effective than placebo in achieving headache relief at 1 hour post-dose in a well designed study. " 07/01/1994 - "In both studies, headache severity had significantly improved at 120 min after doses of 10-40 mg sumatriptan compared to placebo (P < 0.05) and the greatest efficacy rates were obtained with 20 mg sumatriptan. " 04/01/2008 - "We describe an adolescent with acute posttraumatic headache that did not respond to several initial medications but had rapid and sustained improvement in headache and associated migrainous features with subcutaneous sumatriptan." 04/01/2005 - "For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% vs. 33%, p=0.007) and outside (79% vs. 31%, p<0.001) the menstrual period. "
3.	Pain (Aches) 05/28/2014 - " administration was the most effective, with pain reduced from moderate or severe to none by two hours in almost 6 in 10 people (59%) taking 6 mg sumatriptan, compared with approximately 1 in 7 (15%) taking placebo; the number needed to treat (NNT) was 2.3 (95% confidence interval 2.1 to 2.4) with 2522 participants in the analysis. " 07/01/2004 - "The primary objective of this study was to determine the 2-hour efficacy of sumatriptan 100 mg in achieving complete pain relief in patients with a history of nonresponse to sumatriptan 50 mg in an early-intervention treatment paradigm. " 10/01/2021 - "In one trial, patients receiving 3 mg subcutaneous sumatriptan had a significantly lower intensity of pain on average -6.1 points on a scale of 0-10 compared to placebo (P < 0.001) and a significant improvement in pain intensity of -75% compared to the improvement in the placebo group (P < 0.001). " 05/01/2015 - "At each time point measured between 15 and 90 minutes, significantly greater rates of pain relief and pain freedom occurred with AVP-825 treatment compared with oral sumatriptan. " 04/01/2014 - "There was no statistically significant improvement between the sumatriptan pooled group and the placebo group for pain relief at two hours. "
4.	Cluster Headache (Cluster Headaches) 03/01/1998 - "Sumatriptan, an agonist of 5-HT1-like receptors, has proven effective in the treatment of cluster headache attacks. " 11/01/1995 - "Preemptive oral treatment with sumatriptan 100 mg tid for 7 days did not produce a significant reduction in the number or severity of cluster headache attacks occurring during an established cluster headache period. " 01/01/2002 - "Four patients continued to treat all cluster headache attacks with the intranasal sumatriptan formula, two patients had switched to subcutaneous sumatriptan and one patient was in remission since the end of the study. " 09/01/2005 - "We conclude that sumatriptan in doses less than 6 mg can be effective in the acute treatment of cluster headache attacks. " 09/01/2005 - "Subcutaneous (SQ) sumatriptan 6 mg is effective in the treatment of acute cluster headache attacks. "
5.	Nausea 10/07/1995 - "LAS+MTC was significantly more effective in the treatment of nausea than sumatriptan (p < 0.0001) and was better tolerated (adverse events in 18% and 28%, respectively, p < 0.05). " 09/01/2015 - "Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial." 02/01/2018 - "AVP-825 treatment led to more rapid early reductions in Overall Nausea rates during the first hour, reduced odds of nausea from 30 minutes to 2 hours following treatment and reduced risk of TEN compared to oral sumatriptan. " 02/01/2018 - "All three longitudinal models showed that AVP-825 had more favorable nausea outcomes compared to oral sumatriptan. " 02/01/2018 - "The Nausea Relief model (Model 3) showed similar rates of change in nausea over time for the two treatments, but there was a constant difference in nausea level leading to reduced odds of nausea when treating with AVP-825 compared to oral sumatriptan. "

Related Drugs and Biologics

1.	Tablets
2.	Tryptamines (Triptans)
3.	rizatriptan (Maxalt)
4.	zolmitriptan (Zomig)
5.	Ergotamine (Ergotamine Tartrate)
6.	Nasal Sprays
7.	Serotonin (5 Hydroxytryptamine)
8.	Caffeine (No Doz)
9.	Aspirin (Acetylsalicylic Acid)
10.	almotriptan (Axert)

Related Therapies and Procedures

1.	Therapeutics
2.	Subcutaneous Injections
3.	Oral Administration
4.	Intranasal Administration
5.	Aftercare (After-Treatment)